Dr. Lal PathLabs reported Q4 FY26 revenue growth of 16.6% to Rs. 703 crore and full-year growth of 12.2% to Rs. 2,763 crore, driven by sample volume increases.
The company declared a final dividend of Rs. 4 per share, taking the total FY26 dividend to Rs. 20.5 per share post a 1:1 bonus issue.
Management provided FY27 revenue guidance in the early to mid-teens range and plans a capex of Rs. 100-120 crore for lab expansion and new radiology centers.
Key strategic updates included the acquisition of Shahbazkers Diagnostics in Mumbai and the launch of the premium wellness brand Sovaaka.